Human Fibrinogen Concentrate in Pediatric Cardiac Surgery



Status:Recruiting
Conditions:Hematology, Hematology
Therapuetic Areas:Hematology
Healthy:No
Age Range:Any - 1
Updated:3/8/2019
Start Date:January 2017
End Date:April 2020
Contact:Jenny Esteves, RRC
Email:jenny.esteves@nicklaushealth.org
Phone:786-624-2854

Use our guide to learn which trials are right for you!

The Role of Human Fibrinogen Concentrate (RiaSTAP) in Decreasing Blood Loss and the Need for Component Blood Therapy in Infants Undergoing Cardiopulmonary Bypass.

The goal of the study is to determine whether the use of Human Fibrinogen Concentrate
(RiaSTAP) will decrease blood loss and the need for component blood therapy in neonates and
infants undergoing cardiopulmonary bypass.

The goal of the study is to determine whether the use of Human Fibrinogen Concentrate
(RiaSTAP) will decrease blood loss and the need for component blood therapy in neonates and
infants undergoing cardiopulmonary bypass. RiaSTAP will be administered after termination of
Cardiopulmonary Bypass (CPB) at a dose of 70 mg/kg, in a prospective, randomized, controlled
study. We hypothesize that the administration of RiaSTAP in this manner will reduce
peri-operative bleeding and transfusion requirements.

Inclusion Criteria:

- Neonatal and infant cardiac patients presenting for open-heart surgery at Nicklaus
Children's Hospital will be eligible for enrollment in the study.

Exclusion Criteria:

- Patients who fall outside of the age range for the study will be excluded. Patients
known to have had an anaphylactic or severe reaction to the drug or its components
will not be enrolled. At the time of the rewarming ROTEM, any patient with a FIBTEM
MCF > 15mm, will be excluded.
We found this trial at
2
sites
3100 Southwest 62nd Avenue
Miami, Florida 33155
Principal Investigator: Christopher Tirotta, MD
Phone: 786-624-2854
?
mi
from
Miami, FL
Click here to add this to my saved trials
Miami, Florida 33155
Phone: 305-666-6511
?
mi
from
Miami, FL
Click here to add this to my saved trials